Please provide your email address to receive an email when new articles are posted on . The availability of just one or two biosimilars for a given drug may not be enough to increase uptake. Medicare ...
There has been a slew of recent biosimilars news: the steep discounted price of an interchangeable insulin glargine biosimilar, which has yet to launch; adherence rates for infliximab biosimilars and ...
Please provide your email address to receive an email when new articles are posted on . Medicare uptake of infliximab biosimilars remains low, prescribed to only 23% of patients. Medicaid and private ...
LAS VEGAS -- Biosimilar switching was not tied to flare in patients with inflammatory bowel disease (IBD), according to a retrospective cohort study. Patients who switched from infliximab (Remicade) ...
A mandatory, nonmedical switch from infliximab to a biosimilar for inflammatory bowel disease (IBD) indicated that the two treatments have similar clinical outcomes. After 1 year, there were no ...
A second biosimilar to infliximab, marketed as Remicade by Johnson & Johnson, has received FDA approval. Infliximab-abda (Renflexis) was developed by Samsung Bioepis/Merck and has been approved for ...
LAS VEGAS -- In patients with inflammatory bowel disease who lost response after infliximab (Remicade) induction, escalating the maintenance dose of the subcutaneous infliximab biosimilar CT-P13 ...
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Magellan Rx Management, the pharmacy benefit management (PBM) division of Magellan Health, Inc. (NASDAQ: MGLN), released new data today showcasing results from its ...
On February 18, 2021, the American Journal of Health-System Pharmacy published the results of a meta-analysis evaluating the use of infliximab in patients with rheumatoid arthritis (RA). The ...
On October 20, 2020, NeuClone announced that it successfully completed its Phase I clinical trial of NeuLara, its proposed biosimilar of Stelara (ustekinumab). According to Neuclone, the Phase I ...
Researchers sought to explore the effectiveness of switching between the infliximab biosimilars CT-P13 and GP1111. One-year retention following infliximab biosimilar-to-biosimilar switching among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results